ADVERTISEMENT

Clinical Summary

Advanced melanoma or NSCLC: immune checkpoint inhibitors for octogenarians?

Miriam Davis, PhD   |   03 November 2022

Takeaway

  • Patients ≥80 years old have reasonably good survival outcomes and safety with immune checkpoint inhibitors (ICIs) for advanced melanoma or NSCLC, but 18.5% discontinue due to grade 3-4 toxicity, a retrospective cohort found.

Why this matters

  • This is the first real-world study of ICI safety and efficacy expressly for patients...

          

November Challenge

Ends in 10h
left
right

Topic Challenges

left
right